Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HCV Treatment as Prevention in PWIDs

Lancet; 2018 Feb; Zelenev, Li, et al

Among people who inject drugs (PWID) in the US, successful hepatitis C virus (HCV) treatment as prevention should incorporate the baseline HCV and will achieve the greatest benefit when coverage is expanded, a recent study found. Five graph models were fit using data from 1,574 PWID in Hartford, CT. Researchers simulated transmission of HCV and HIV through this network with varying levels of HCV treatment coverage and varying baseline HCV prevalence in PWID. They then compared the effectiveness of 7 treatment-as-prevention strategies on reducing HCV prevalence over 10 years and 20 years vs no treatment. They found:

  • At the highest baseline HCV prevalence in PWID (85%), expansion of treatment does not substantially reduce HCV prevalence for any treatment-as-prevention strategy.
  • However, when baseline HCV prevalence is ≤60%, treating >120 (12%) individuals per 1,000 PWID per year would likely eliminate HCV within 10 years.
  • On average, assigning treatment randomly to individuals who inject drugs is better than targeting individuals with the most injection partners.

Citation:

Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: A modelling study. Lancet. 2018;18(2):215-224. doi:10.1016/S1473-3099(17)30676-X.

This Week's Must Reads

CDC Metric for Measuring & Comparing Antibiotic Use, Clin Infect Dis; ePub 2018 Feb 2; van Santen, et al

Racial Disparities in Lifetime Risk of Chlamydia, Clin Infect Dis; ePub 2018 Feb 6; Chambers, et al

Regional Spread of CRE Among Healthcare Facilities, Clin Infect Dis; ePub 2018 Feb 3; Ray, et al

Daily vs Nondaily Oral PrEP in At-Risk Groups, Clin Infect Dis; ePub 2018 Feb 6; Grant, et al

HCV Treatment as Prevention in PWIDs, Lancet; 2018 Feb; Zelenev, Li, et al

Must Reads in Hepatitis

HCV Treatment as Prevention in PWIDs, Lancet; 2018 Feb; Zelenev, Li, et al

Microbial Translocation & Immune Activation in HIV and HCV, J Infect Dis; ePub 2018 Jan 3; Reid, Ma, et al

Opioid Substitution Therapy in HCV Patients, J Infect Dis; ePub 2017 Dec 26; Stepanova, et al

Improving Access to HCV Infection Treatment, Open Forum Infect Dis; ePub 2017 Dec 9; Collins, et al

HbA1c Improvement After HCV Clearance in HIV?, J Infect Dis; ePub 2017 Nov 18; Chaudhury, et al